Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 20, 2011

FDA revokes Avastin’s breast cancer approval

US Food and Drug Administration (FDA) commissioner Margaret Hamburg has confirmed that the agency is revoking its approval of the breast cancer indication for Roche's Avastin medication.

By Liam Stoker

US Food and Drug Administration (FDA) commissioner Margaret Hamburg has confirmed that the agency is revoking its approval of the breast cancer indication for Roche’s Avastin medication.

The drug will, however, remain on the market as an approved treatment for particular forms of colon, lung, kidney and brain cancer.

Risks associated with Avastin include high blood pressure, bleeding and haemorrhaging as well as heart attack or failure.

The announcement stems from a decision made in July 2010, in which the FDA Oncologic Drugs Advisory Committee voted 12-1 in favour of removing the drug’s approval.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU